Get the Daily Brief
Latest Biotech News
Funding for new eczema bispecific in clinical development
Triveni Bio secured $65 million in a Series C round to advance TRIV-573, its bispecific therapy for atopic dermatitis. The financing is earmarked for clinical development, signaling continued...
Big Pharma turns to accelerated dealmaking in biotech
Pharma is stepping up acquisition activity, with coverage describing a surge in biotech deals valued at $1 billion or more over the last six months. The report cites 32 such transactions and about...
AI-driven drug discovery alliance for neuroimmune targets
Insilico Medicine and SK Biopharmaceuticals expanded their partnership with a large, heavily backloaded AI drug discovery deal focused on neuroimmune disorders. Coverage says the deal value could...
U.S. trade probe targets Germany drug pricing amid R&D burden dispute
The U.S. Trade Representative launched an investigation into Germany’s drug pricing policies, arguing the U.S. bears a disproportionate share of global biopharma R&D costs. The probe was opened by...
Global HTA value frameworks under fire over pricing negotiations
A new report from No Patient Left Behind (NPLB) argues that drug value assessments used by countries such as Canada and Germany systematically undervalue innovative medicines—citing gaps as large...
Phase I safety readout for biased mu-opioid agonist SHR8554
SHR8554 advanced to a Phase I safety checkpoint as the compound’s pharmacokinetics and pharmacodynamics were reported alongside tolerability outcomes. The investigational biased µ-opioid receptor...
Long-horizon long-term follow-up after stem cell transplant for autoimmune disease
A rare autoimmune-disease case series reported sustained remission more than 15 years after a stem-cell transplant. The results were published in the journal Med, describing two patients with a...
Nature Communications study unpacks AOC1-driven autophagy control of labor onset
Researchers led by Chen, Long, Wang, and colleagues described a molecular pathway they say regulates labor onset through AOC1 and spermidine-driven autophagy in placental trophoblast cells. The...
Meta-analysis quantifies second primary malignancy risk after T-cell engaging bispecifics
A systematic review and meta-analysis estimated the frequency of second primary malignant neoplasms (SPMs) after T-cell engaging bispecific antibody therapy in adults with non-Hodgkin lymphoma and...
CRISPR gene editing progress in hereditary angioedema
Intellia Therapeutics advanced its hereditary angioedema (HAE) program after delivering a second set of positive Phase III readouts for lonvoguran ziclumeran (lonvo-z). The company said the...
US-Germany trade probe targets drug pricing and R&D cost allocation
The U.S. government launched a Section 301 investigation into Germany’s drug pricing policies, arguing the country shifts an outsized share of global R&D costs onto the United States. USTR...
Value assessment disputes spur pressure on HTA frameworks
A new report from No Patient Left Behind (NPLB) accused non-U.S. health technology assessment (HTA) systems—especially in Canada and Germany—of undervaluing innovative medicines by as much as 90%....
Biologics long-term safety signal for T-cell engaging bispecifics
A systematic review and meta-analysis quantified second primary malignant neoplasms (SPMs) after T-cell-engaging bispecific antibody therapy in adults with B-cell non-Hodgkin lymphoma and multiple...
Biased μ-opioid agonist enters early clinical safety readout
SHR8554 advanced into human testing with a Phase I trial reporting a safety profile alongside pharmacokinetics and pharmacodynamics for a novel biased μ-opioid receptor agonist. The report frames...
Advanced AI modeling for atomic-scale protein interactions
A new generative AI model was introduced to predict protein–protein interactions at the atomic scale, targeting one of the most computationally intensive steps in structural biology and...
Clinical AI and dataset trust requirements for life sciences
A new perspective argued that AI-driven drug discovery depends on trustworthy biological data—specifically requiring authenticated datasets, validation, and standardized metadata. The piece frames...
Mitigation and monitoring in assisted reproduction: hCG trigger effects
A study scheduled for Nature Communications in 2026 reported that exposure to human chorionic gonadotropin (hCG) on the trigger day can affect downstream DNA methylation patterns and...
Cancer biology: PER2 links circadian control to cholesterol synthesis in OSCC
Researchers identified a circadian gene, PER2, as a driver of cholesterol synthesis in oral squamous cell carcinoma (OSCC) and showed it can be targeted to block tumor growth. The work, described...
Oncology mechanism: RBM41 blocks NDRG1 maturation to drive colorectal cancer
A mechanistic study implicated RNA binding motif protein 41 (RBM41) as a facilitator of colorectal tumorigenesis by interfering with NDRG1 maturation. The report positions RBM41 as an oncogenic...
Trade probe targets European drug pricing
The U.S. Trade Representative launched a Section 301 investigation into Germany’s drug pricing policies, arguing the U.S. shoulders a disproportionate share of global biopharma R&D costs. USTR...